Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies

Xenobiotica

Volumn 38, Issue 12, 2008, Pages 1500-1517

  Kenny, J R ^a   Chen, L ^b   McGinnity, D F ^a   Grime, K ^a   Shakesheff, K M ^b   Thomson, B ^b   Riley, R ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cytochrome P450; Cytochrome P450 (CYP) induction; Drug drug interactions; Fa2N 4 cells; Time dependent inhibition

Indexed keywords

AMFEBUTAMONE; AROMATIC HYDROCARBON RECEPTOR; BETA NAPHTHOFLAVONE; BUFURALOL; CARBAMAZEPINE; CLOTRIMAZOLE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; EFAVIRENZ; MEPHENYTOIN; MESSENGER RNA; MIDAZOLAM; NIFEDIPINE; PACLITAXEL; PHENACETIN; PHENOBARBITAL; PREGNANE X RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RESERPINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SULFINPYRAZONE; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; CELL CULTURE; CELL LINE; CENTRIFUGATION; CYTOLYSIS; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME SUBSTRATE; FA2N 4 CELL; GENE CASSETTE; GENE EXPRESSION; GENETIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; LIQUID CHROMATOGRAPHY; LIVER CELL; MICROSOME; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY;

ARYL HYDROCARBON HYDROXYLASES; CELL LINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HUMANS; LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 56749185575     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802495846     Document Type: Article

References (46)

1. Atkinson A, Kenny JR, Grime K. 2005. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metabolism and Disposition 33:1637-1647.
2. Berghard A, Gradin K, Pongratz I, Whitelaw M, Poellinger L. 1993. Cross-coupling of signal transduction pathways: The dioxin receptor mediates induction of cytochrome P-450IA1 expression via a protein kinase C-dependent mechanism. Molecular Cell Biology 13:677-689.
3. Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ. 2006. Hepatocyte cell lines: Their use, scope and limitations in drug metabolism studies. Expert Opinion on Drug Metabolism and Toxicology 2:183-212.
4. Dickins M. 2004. Induction of cytochromes P450. Current Topics in Medicinal Chemistry 4:1745-1766.
5. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. 2007. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metabolism and Disposition 35:1853-1859.
6. Drocourt L, Pascussi J-M, Assenat E, Fabre J-M, Maurel P, Vilarem M-J. 2001. Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metabolism and Disposition 29:1325-1331.
7. Ernest II CS, Hall SD, Jones DR. 2005. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of Pharmacology and Experimental Therapeutics 312:583-591.
8. Faucette SR, Sueyoshi T, Smith CM, Negishi M, LeCluyse EL, Wang H. 2006. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. Journal of Pharmacology and Experimental Therapeutics 317:1200-1209.
9. Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL. 2004. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metabolism and Disposition 32:348-358.
10. Faucette SR, Zhang T, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H. 2007. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. Journal of Pharmacology and Experimental Therapeutics 320:72-80.
11. Hariparsad N, Carr BA, Evers R, Chu X. 2008. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metabolism and Disposition 36:1046-1055.
12. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. 2004. Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and phenobarbital. Journal of Clinical Pharmacology 44:1273-1281.
13. Harmsen S, Koster A, Beijnen JH, Schellens JH, Meijerman I. 2008. Comparison of two immortalized human cell lines to study nuclear receptor mediated CYP3A4 induction. Drug Metabolism and Disposition 36:1166-1171.
14. Hewitt NJ, Lecluyse EL, Ferguson SS. 2007a. Induction of hepatic cytochrome P450 enzymes: Methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 7:1196-1224.
15. Hewitt NJ, Lechon MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. 2007b. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metabolism Reviews 39:159-234.
16. Kanebratt KP, Andersson TB. 2008. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metabolism and Disposition 36:1137-1145.
17. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, et al. 2004. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metabolism and Disposition 32:512-518.
18. LeCluyse E, Madan A, Hamilton G, Carroll K, DeHaan R, Parkinson A. 2000. Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. Journal of Biochemical and Molecular Toxicology 14:177-188.
19. LeCluyse EL. 2001. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. European Journal of Pharmaceutical Sciences 13:343-368.
20. Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK. 1997. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin. Chemico-Biological Interactions 107:17-30.
21. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, et al. 2002. CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metabolism and Disposition 30:795-804.
22. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. 2003. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metabolism and Disposition 31:421-431.
23. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, et al. 2003. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. Journal of Biological Chemistry 278:17277-17283.
24. Masubuchi Y. 2006. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review. Drug Metabolism and Pharmacokinetics 21:347-356.
25. McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ. 2006. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metabolism and Disposition 34:1291-1300.
26. Meneses-Lorente G, Pattison C, Guyomard C, Chesné C, Heavens R, Watt AP, Sohal B. 2007. Utility of long-term cultured human hepatocytes as an in vitro model for cytochrome p450 induction. Drug Metabolism and Disposition 35:215-220.
27. Meunier V, Bourrié M, Julian B, Marti E, Guillou F, Berger Y, Fabre G. 2000. Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: A 10-year follow-up. Xenobiotica 30:589-607.
28. Mills JB, Rose KA, Sadagopan N, Sahi J, De Morais SM. 2004. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. Journal of Pharmacology and Experimental Therapeutics 309:303-309.
29. Mohutsky MA, Petullo DM, Wrighton SA. 2005. The use of a substrate cassette strategy to improve the capacity and throughput of cytochrome P450 induction studies in human hepatocytes. Drug Metabolism and Disposition 33:920-923.
30. Nallani SC, Goodwin B, Buckley AR, Buckley DJ, Desai PB. 2004. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemotherapy and Pharmacology 54:219-229.
31. Nishimura M, Koeda A, Suganuma Y, Suzuki E, Shimizu T, Nakayama M, Satoh T, Narimatsu S, Naito S. 2007. Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metabolism and Pharmacokinetics 22:178-186.
32. Persson KP, Ekehed S, Otter C, Lutz ES, McPheat J, Masimirembwa CM, Andersson TB. 2006. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome P450 induction potential of drugs in vivo in humans. Pharmaceutical Research 23:56-69.
33. Ramachandran V, Kostrubsky VE, Komoroski BJ, Zhang S, Dorko K, Esplen JE, Strom SC, Venkataramanan R. 1999. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metabolism and Disposition 27:1194-1199.
34. Raucy JL. 2003. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metabolism and Disposition 31:533-539.
35. Reinach B, De Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. 1999. Comparative effects of rifabutin and rifampicin on cytochromes P 450 and UDP-glucuronosyltransferases expression in fresh and cryopreserved human hepatocytes. Chemico-Biological Interactions 121:37-48.
36. Riley RJ. 2001. The potential pharmacological and toxicological impact of P450 screening. Current Opinion on Drug Discovery and Development 4:45-54.
37. Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, De Morais SM. 2006. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metabolism and Disposition 34:1742-1748.
38. Roymans D, Van Looveren C, Leone A, Parker JB, McMillian M, Johnson MD, Koganti A, Gilissen R, Silber P, Mannens G, et al. 2004. Determination of cytochrome P450 1A2 and cytochrome P450 3A4 induction in cryopreserved human hepatocytes. Biochemical Pharmacology 67:427-437.
39. Sahi J, Hamilton G, Sinz M, Barros S, Huang SM, Lesko LJ, LeCluyse EL. 2000. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 30:273-284.
40. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, Rodrigues AD. 2006. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Current Drug Metabolism 7:375-388.
41. Steen D. 2004. Immortalized human hepatocytes: A new advance in convenience and performance. Current Separations 20:137-140.
42. Vermeir M, Annaert P, Mamidi RN, Roymans D, Meuldermans W, Mannens G. 2005. Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opinion on Drug Metabolism and Toxicology 1:75-90.
43. Wang H, LeCluyse EL. 2003. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clinical Pharmacokinetics 42:1331-1357.
44. Weaver R, Graham K, Beatie IG, Riley RJ. 2003. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metabolism and Disposition 31:955-966.
45. Whitlock Jr. JP. 1999. Induction of cytochrome P4501A1. Annual Review of Pharmacology and Toxicology 39:103-125.
46. Youdim KA, Tyman CA, Jones BC, Hyland R. 2007. Induction of cytochrome P450: Assessment in an immortalized human hepatocyte cell line (Fa2N-4) using a novel higher throughput cocktail assay. Drug Metabolism and Disposition 35:275-282.